By Christoph Frick and Nicola Spiggelkötter. Creating a Master Plan for Drug Warehousing, Transportation and Distribution
|
|
- Paula Goodwin
- 5 years ago
- Views:
Transcription
1 By Christoph Frick and Nicola Spiggelkötter Creating a Master Plan for Drug Warehousing, Transportation and Distribution
2 ISBN: Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in this book. While every effort has been made by Maas & Peither AG GMP Publishing, to ensure the accuracy of the information contained in this book, this organisation accepts no responsibilty for errors or omissions. Copyright 2014 by Maas & Peither AG GMP Publishing, All Rights Reserved This book is based on a chapter of the GMP MANUAL, Good Manufacturing Practice and Implementation. The material has been adapted and edited incollaboration with the FDAnews, 300 N. Washington St., Suite 200, Falls Church, VA Maas & Peither AG GMP Publishing Karlstrasse Schopfheim Germany Neither this e-book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording or by any information storage and retrieval system without permission in writing from the publisher.
3 Creating a Master Plan for Drug Warehousing, Transportation and Distribution Table of Contents About the Authors...2 Introduction...3 Regulatory Principles: EU, U.S., Canada and WHO...5 Transport Conditions: Transport As Mobile Storage...15 Transport Vehicles and Transport Packaging...22 Modes of Transportation: Guidelines and Quality Standards for Land Transportation...30 Monitoring Transport Temperatures...38 Risk Management in Transportation...45 Qualification of Large-Scale Active Systems (Trailers)...50 Qualification of Passive Insulation Boxes...58 Logistics Service Providers...68 Transport Validation...84 References...94
4 About the Authors Christoph Frick is the head of pharmaceutical development at Kohlpharma in Germany. He has worked for years at Kohlpharma and other companies with a focus on quality assurance, good manufacturing practice, good documentation practice, cool chain processes, risk management, qualification and validation, auditing, business development and regulatory affairs. Nicola Spiggelkötter is a pharma consultant with years of experience in quality assurance and API sourcing, cold chain, process optimization, audits, staff training and risk management.
5 Introduction Creating a Master Plan for Drug Warehousing, Transportation and Distribution The production of high-quality, safe medicinal products is the objective of every pharmaceutical company and is subject to GMP rules. Even though a medicinal product may be of impeccable quality when it leaves the manufacturing facility, during transport to the consumer it is exposed to many influences beyond the manufacturer s control that can compromise the product s quality. Therefore, it is not surprising that pharmaceutical transport or carriage in accordance with good distribution practice has recently become a topic of steadily growing importance. This change in awareness can be observed in inspections by authorities and in the quality assurance departments of pharmaceutical companies. However, the requirements made in the usual regulatory structures are not homogenous. Numerous guidelines are undergoing revision and new ones are being issued. For example, the revised EU GDP guidelines became effective Nov. 24, The catchphrase supply chain integrity is making the rounds, and refers to a closely knit supply chain as it relates to the infiltration of falsified medicinal products. Keeping falsified medicinal products from infiltrating the distribution chain is a core objective that affects the following aspects of transport processes: Admission/access control during the transport process Authentication and verification of sources of supply and delivery addresses Documentation of the individual delivery steps along the lines of a drug pedigree However, in terms of medicinal product safety, preventing the infiltration of falsified medicinal products into the distribution chain (or the theft of medicinal products from the distribution chain) is not the only aspect of pharmaceutical transport to be considered. Maintaining the required temperatures during transport poses another major challenge. Temperature during transport can greatly affect the quality of the products that reach consumers, as the following practical example illustrates: Wholesale distributors often use frozen cool packs for shipments of medicinal products that require refrigeration, and they generally do so regardless of prevailing outside temperatures. The likelihood that the refrigerated medicinal product will warm up is viewed as the sole risk factor, while little attention is paid to the other extreme, namely freezing. But it is this very drop to below the temperature range of 2 C to 8 C that can be extremely critical. Only a few minutes of exposure of an aluminum adsorbate vaccine to below-freezing temperatures can cause irreversible damage to the product (denaturation). Failure to deal with the problem entails the risk of compromising the product s safety and endangering the patient. This can undermine all GMP-compliant activities of a pharmaceutical company down to the last few steps in the distribution chain. Increasing awareness of transport and temperature is all the more important in light of the fact that one-fifth of the global pharmaceuticals market is occupied by preparations that are subject to cold chain requirements and the trend is growing. 1 Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C ), 3
6 Creating a Master Plan for Drug Transportation and Distribution Medicinal products subject to the cold chain are generally high-priced medicines. If workflows are not scrutinized and validated adequately, transport damage could well lead to revenue and sales losses amounting to millions. Measured against a financial risk of this magnitude, the effort involved in transport validation is reasonable and economically feasible. Intermediate storage under a third party s responsibility may become necessary in the course of distribution, for instance on Sundays or holidays. Performing a prospective and/or retrospective qualification of a cold-storage facility is therefore also an important prerequisite for controlled storage conditions. Several cooperation partners are usually involved in the distribution chain. However, there may be marked differences in their GMP background and the regulatory structures applying to them. Each one, however, is responsible for pharmaceutical safety. Coordinating a distribution chain of this nature represents a major challenge that must be met. 4
7 Creating a Master Plan for Drug Warehousing, Transportation and Distribution Regulatory Principles: EU, U.S., Canada and WHO The revised Guidelines on Good Distribution Practice of Medicinal Products for Human Use became effective Nov. 24, Implementation of the guidelines is intended to support wholesale distributors and to help prevent the infiltration of falsified medicinal products into the legal distribution chain. The safety and integrity of the supply chain is of paramount importance here. Others involved in the supply chain are expressly included: Relevant sections of these guidelines should also be adhered to by other actors involved in the distribution of medicinal products. Transportation providers top the list of those actors. EU GDP Guidelines: Chapter 1 Quality Management Chapter 1 Quality Management deals with quality systems and the role played by management. A comprehensive quality assurance system should be implemented and documented. The demand that principles of quality risk management be applied here presents a challenge to many wholesale distributors. This risk-oriented approach is a theme that runs throughout the guidelines. Explicit references to ICH Q9: Quality Risk Management are also made. A quality assurance system has six key tasks assigned to it: Procurement, storage, delivery and export of medicinal products in conformity with good distribution practices Definition of managerial competence and responsibility Shipment of medicinal products Prompt provision of documentation Documentation and follow-up on deviations Initiation of CAPA actions Chapter 2 Personnel The appointment of a responsible person and that person s ideal qualification ( A degree in pharmacy is desirable ) have clearly raised the standard of desirable qualifications. Here, too, the proximity to the GMP-regulated sector becomes clearly evident. Furthermore, the guideline says constant availability (24/7) of the responsible person is expected, especially when it comes to product recalls. This requirement may entail rerouting phone calls and being on call, so to speak. For example, for some time now this has been customary practice for issuing alerts, when the monitoring system detects a failure or a deviation from the specified temperature. Some of the key tasks are: Implementing and maintaining a quality management system Monitoring processes and workflows that have been approved 5
By Dr. Michael Hiob, Max Lazar, Dr. Christian Gausepohl and Dr. Christine Oechslein. Preparing for the EU GMP Inspection
By Dr. Michael Hiob, Max Lazar, Dr. Christian Gausepohl and Dr. Christine Oechslein Preparing for the EU GMP Inspection ISBN: 978-3-943267-79-2 A Process Approach to Pharmaceutical Quality Systems A Guide
More informationChristine Oechslein. GMP Focus. Managing Process Validation. A Drugmaker s Guide. PDF Download. Excerpt from the GMP MANUAL
Christine Oechslein GMP Focus Managing Process Validation A Drugmaker s Guide PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de ISBN: 978-3-95807-056-1
More informationChristian Gausepohl, Frank Böttcher. GMP Focus. Managing Contract Manufacturers and Testing Labs. PDF Download. Excerpt from the GMP MANUAL
Christian Gausepohl, Frank Böttcher GMP Focus Managing Contract Manufacturers and Testing Labs PDF Download Excerpt from the GMP MANUAL Bibliographic Data of the Deutsche Nationalbibliothek: http://dnb.ddb.de
More informationApplying a Knowledge-Based Approach to Pharmaceutical Supply Chain Temperature Control Management
May 1-3, 2012 Javits Center New York, NY Applying a Knowledge-Based Approach to Pharmaceutical Supply Chain Control Management Arminda O. Montero Program Manager, Distribution QA Global Pharmaceutical
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationMHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents
MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Complex Business Models - Outsourced Activities Presented by: Jacqueline Masayi, GDP Inspector Background Increased complexities of the
More informationOverview sulla nuova guideline GDP
AFTI 09 febbraio 2012 Overview sulla nuova guideline GDP Fabio Dotto Ispettorato Regionale Medicamenti Svizzera del Sud 1 113 GDP Guidelines GDP of Medicinal Products for Human Use Public consultation
More informationFeedback from Inspection Programme
Feedback from Inspection Programme Wholesale Distribution Conference 8 th February 2017 Darren Scully Health Products Distribution Manager Wholesale distribution overview wholesale distribution procure
More informationDrug and Device Makers Cited in 483s for CAPAs, Poor Documentation in 2014
Drug and Device Makers Cited in 483s for CAPAs, Poor Documentation in 2014 Copyright 2015 by FDAnews. All rights reserved. Photocopying or reproducing this report in any form, including electronic or facsimile
More informationPharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES
Pharma and Logistic Service Providers (LSP) Synergies and opportunities GDP, NEW EUROPEAN DIRECTIVES DB Schenker Healthcare Conference Europe April 17-18 th 2012 J. BERLO Industrial Pharmacist/Clin. Biol.
More informationOverview SFLGDP1. Develop, implement and maintain a quality system to control the distribution of medicinal products
Overview This standard is about developing, implementing and maintaining a quality system to control the. You will be responsible for developing the quality system and confirming colleagues understand
More informationImplementation of EU Falsified Medicines Directive
Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationPHASE APPROPRIATE GMP FOR BIOLOGICAL PROCESSES
PHASE APPROPRIATE GMP FOR BIOLOGICAL PROCESSES PRE-CLINICAL TO COMMERCIAL PRODUCTION Trevor Deeks Editor Phase Appropriate GMP for Biological Processes Pre-clinical to commercial production Trevor Deeks
More informationOverview SFLGDP1- HP Develop, implement and maintain a quality system to control the distribution of medicinal products
- HP97 04 Overview What this standard is about This standard is about developing, implementing and maintaining a quality system to control the. You will be responsible for developing the quality system
More informationThe benchmark in cold chain. 30+ years experience in cold chain
The benchmark in cold chain 30+ years experience in cold chain Why Temperature Controlled Transportation? A drug that has been temperature abused is every bit as dangerous as one that is not authentic
More informationGood Documentation Practices. Documentation Requirements For Regulated Environments
Good Documentation Practices Documentation Requirements For Regulated Environments Agenda Example Deficiency 2014 Result Of Poor Record Creation Data Integrity EU GMP Chapter 4 Requirements Non GMP Compliant
More informationUNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products
UNICEF s Quality Assurance System for Procurement of Finished Pharmaceutical Products UNICEF Industry Consultation with Manufacturers and Suppliers of Finished Pharmaceutical Products 29 th 30 th September
More informationTextvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf
Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern
More informationHealthcare logistics. Business Solution. Individual logistic solutions out of one hand
Business Solution Healthcare logistics Arvato provides individual logistics solutions for pharmaceutical and medical technology companies across Europe for all product categories and temperature ranges.
More informationChange Control Dealing with Changes in Investigational Medicinal Products
Change Control Dealing with Changes in Investigational Medicinal Products by Kerstin Kruithoff-Ley Changes accompany us throughout our lives. We have to be able to deal with them successfully and use them
More informationMHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents
MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Deficiencies in GDP Phil Neale, GDP Operations Manager Tony Orme, GDP Senior Inspector. Finding deficiencies in GDP is not only for those
More informationGIRP-IPF Study 2016 KEY FINDINGS EUROPEAN HEALTHCARE DISTRIBUTION ASSOCIATION GROUPEMENT INTERNATIONAL DE LA RÉPARTITION PHARMACEUTIQUE
GIRP-IPF Study 2016 KEY FINDINGS EUROPEAN HEALTHCARE DISTRIBUTION ASSOCIATION GROUPEMENT INTERNATIONAL DE LA RÉPARTITION PHARMACEUTIQUE The role of the pharmaceutical wholesale sector 2 ROLE OF PHARMACEUTICAL
More informationPharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit
Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing
More informationBiologicals: cold chain and temperature control from product design to finished product
Biologicals: cold chain and temperature control from product design to finished product Symposium Biologicals, Bonn, Oct. 2008 Symposium der Fachgruppe Arzneimittelkontrolle/Pharmazeutische Analytik in
More informationLogistic Provider Qualification: prerequisites and SLA
Logistic Provider Qualification: prerequisites and SLA Summary of the Content Benchmarking comparable providers and services to cope with product and market requirements Pre-qualification Activities Operational
More informationQS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain
QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain Presented by: Karen Ginsbury For IFF 01 March, 2017 Pharma Supply Chain Manufacturer Wholesaler Raw Material Supply Production Transport Warehouse
More informationA PROCESS VALIDATION GUIDE FOR COLD CHAIN LOGISTICS: ENSURING COMPLIANCE GLOBALLY
A PROCESS VALIDATION GUIDE FOR COLD CHAIN LOGISTICS: ENSURING COMPLIANCE GLOBALLY Presented by: Gary Hutchinson, President, Modality Solutions 8 th BSMA Conference Preparing the Biotech Supply Chain for
More informationQuality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology
PharmaTutor PRINT ISSN: 294-6679 E-ISSN: 247-788 2 Quality Risk Management (QRM) of active pharmaceutical ingredients during transportation by using FMEA tools and methodology Upendra Kumar Singh*, Sammer
More informationGDP Audits : Weak points when conducting GDP Audit based on inspections
GDP Audits : Weak points when conducting GDP Audit based on inspections s COOL SUPPLY System & Solutions 2017 Webinar 15 February 2017 Riekert Bruinink Dutch Healthcare Inspectorate 2 Titel van presentatie
More informationUNICEF Quality Assurance in the procurement of medicines
UNICEF Quality Assurance in the procurement of medicines Peter S. Jakobsen 30 October 2006 Quality Assurance Centre SUPPLY DIVISION Today s presentation addresses 3 questions: How is UNICEF involved in
More informationGUIDANCE NOTE 37 MEDICAL GASES DATA INTEGRITY
GUIDANCE NOTE 37 MEDICAL GASES DATA INTEGRITY 2017 GUIDANCE NOTE 37 MEDICAL GASES DATA INTEGRITY 2017 Copyright 2017 by British Compressed Gases Association. First printed 2017. All rights reserved. No
More informationCounterfeit Drugs and Supply Chain Security
Counterfeit Drugs and Supply Chain Security Rick Mitzner Senior Director, Engineering Technology Pfizer, Inc. Interphex April 21, 2015 Tragic Consequences Not If But When and Where May 7, 2007 80 children
More information(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION
21.3.2015 EN Official Journal of the European Union C 95/1 II (Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Guidelines of 19 March 2015 on
More informationNew GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016
New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised
More informationMary G. Foster, PharmD, USP Chair Packaging, Storage & Distribution Expert Committee June 9, 2015, San Francisco
AAPS Mini Symposium Frozen State Storage and Cold Chain Transportation Storage & Shipping of Biopharmaceuticals USP General Chapter Good Distribution Practices Latest Guidance Developments Mary
More informationProcess development and basic GMP
Process development and basic GMP Aulton Chapter 45, handouts Specification, stability, inprocess controls and validation Product development Process development Critical Product Qualities issues Critical
More informationPROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT
August 2010 RESTRICTED PROPOSED NEW SECTIONS FOR WHO GOOD MANUFACTURING PRACTICES (GMP): MAIN PRINCIPLES FOR PHARMACEUTICAL PRODUCTS DRAFT FOR COMMENT Please address any comments on this draft guideline
More informationCommission Guidelines on Good Distribution Practice of Medicinal Products for Human Use
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/an D(2010) 380358 Commission Guidelines on Good Distribution Practice
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationIMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU. IPA/EDQM/WHO 2012, Mumbai
IMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU from the perspective of Indian manufacturers and Indian authorities IPA/EDQM/WHO 2012, Mumbai S.M.MUDDA Micro Labs Limited, Bangalore
More informationCold Chain Committee Guidance for shippers, transport service providers and subcontractors
Guidance for shippers, transport service providers and subcontractors involved in the distribution of pharmaceutical products registered for storage between 2 and 8 Celsius Guidance for Shippers 1 of 7
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationEvaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager
Evaluation of Counterfeit Cases Impact of FMD & GDPs Wholesale Distribution Information Day, 28th September 2012 Lorraine Nolan Healthcare Products Distribution Manager Slide 1 Contents 1. Review of UK
More information25 February 2010 Slide 1
Cold chain Wholesale Distribution Information Day, 25/2/2010 Greg McGurk Executive Inspector 25 February 2010 Slide 1 Cold Chain Scope: Factors affecting transportation Small scale transportation Large
More informationGuidelines on Good Distribution Practice of Medicinal Products for Human Use. CF edition
Introduction Introduction These guidelines have been prepared in accordance with Article 10 of Council The present guidelines are based on Articles 84 and 85a(3) of Directive Directive 92/25/EEC of 31
More informationGUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 047-1 Annex 1 July 2018 GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL
More informationSupplier Assurance Program. CBE Pty Ltd
Supplier Assurance Program CBE Pty Ltd This training program is copyright to CBE Pty Ltd and may not be modified, reproduced, sold, loaned, hired or traded in any form without its express written permission.
More information2012 Academy Seminar - Thessaloniki, Greece Storage and transportation of pharmacy compounded drugs
2012 Academy Seminar - Thessaloniki, Greece Storage and transportation of pharmacy compounded drugs 21 April 2012, Barbara Wimmer, barbara.wimmer@gespag.at Conflict of interest: nothing to disclose 1.
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationPresse-Information Press release Information de presse
Presse-Information Press release Information de presse Kontakt/Contact: Dr. Kathrin Rübberdt Tel. ++49 (0) 69 / 75 64-2 77 Fax ++49 (0) 69 / 75 64-2 72 e-mail: presse@dechema.de Trend Report February 2018
More informationGMP Track 1 Day 2 Session 1 Vendor Assurance
GMP Track 1 Day 2 Session 1 Vendor Assurance 11 August 2015 150403_POUT This session Three presentations Chapter 6 and 7 - Trevor Schoerie Quality Control Out sourced Activities Draft - FDA Quality Metrics
More informationSelf-Inspection and its potential benefits via ICH Q9 & Q10
Self-Inspection and its potential benefits via ICH Q9 & Q10 Kevin O Donnell, Ph.D. Senior Inspector & Market Compliance Manager Irish Medicines Board IMB Information Day October 23 rd, 2008 Slide 1 Topics
More informationTaking a Leap Toward Global Supply Chain Efficiency - Part II
Taking a Leap Toward Global Supply Chain Efficiency - Part II 2 Supply Chain Brochure - Part II INTRODUCTION Pharmaceutical manufacturers face a number of challenges in the production and delivery of medicinal
More informationDSV Healthcare. Devices and Diagnostics
DSV Healthcare Devices and Diagnostics Organizational overview DSV Healthcare is South Africa s leading distributor of pharmaceutical and healthcare products, and part of DSV South Africa, wholly owned
More informationWhite paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU
White paper: Code of GMP Chapter 4 Documentation - PIC/S versus EU Numerous articles are available comparing the current and previous EU Code of GMP Chapter 4: Documentation, but no comparison exists between
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationQ10 PHARMACEUTICAL QUALITY SYSTEM
Q10 PHARMACEUTICAL QUALITY SYSTEM This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights
More informationQUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION
PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/W 1/2011 2 Annexes 22 July 2011 QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PIC/S 2011 Reproduction
More informationOursourcing and Supplier Qualification from the perspective of the pharmaceutical Industry
Oursourcing and Supplier Qualification from the perspective of the pharmaceutical Industry 1 Presentation Outline Pharmaceutical Quality Management Partner Selection and Qualification Shipping Qualification
More informationProcess and Architecture Overview IDMP Identification of Medicinal Products. Sven Eller, Life Sciences Solution Engagement Manager
Process and Architecture Overview IDMP Identification of Medicinal Products Sven Eller, Life Sciences Solution Engagement Manager Legal Disclaimer The information in this document is confidential and proprietary
More informationEurope s new approach to assurance of API quality and its implications for manufacturers and producing countries
Europe s new approach to assurance of API quality and its implications for manufacturers and producing countries IPA / EDQM / WHO Mumbai Conference 28 September 2012 Dr Florence Benoit-Guyod, EDQM Inspector,
More informationCHINA. Australia - China Life Science Summit. . Bio & Pharma Logistics
CHINA. Bio & Pharma Logistics Andrew McDonald Operations Director, Asia Pacific Melbourne, Australia, 27th March 2013 Australia - China Life Science Summit Responsibilities Who takes responsibility on
More informationValidation and Verification of Supply Chain: End-to-End Karen S Ginsbury For IVT: Workshop C 28 October :30 12:00
Validation and Verification of Supply Chain: End-to-End Karen S Ginsbury For IVT: Workshop C 28 October 2014 08:30 12:00 Pangea 7 May 2014 Israel ONLY Pangea 7 May 2014 Israel ONLY Pangea 7 May 2014 Israel
More informationHealthy solutions for the healthcare industry.
Healthy solutions for the healthcare industry. Vertical Market Healthcare Solutions Photo: thinkstock We take care of the products that take care of people. The reliable delivery of healthcare products
More informationRegulatory. Supplier Qualification A Review
Supplier Qualification A Review Abstract: It is a GMP requirement to certify the vendor to deliver high quality and safe medicines, and to prevent recalls, deaths, adverse events, and serious illness due
More informationPractical and Value Generating Approach to IATA Chapter 17 7 th Edition of the Perishable Cargo Regulations -- David Y. Bang
Practical and Value Generating Approach to IATA Chapter 17 7 th Edition of the Perishable Cargo Regulations -- David Y. Bang With much anticipation and efforts by those who work daily with perishable cargo,
More informationSession 4: Quality Defect Investigations and Product Recalls
Session 4: Quality Defect Investigations and Product Recalls Amy Kelly Ph.D. and Kevin O Donnell Ph.D. GMP Conference 12 th November 2014 Outline The application of QRM principles to QD investigations
More informationProduct serialization and traceability mandates. kpmg.com
Product serialization and traceability mandates kpmg.com 1 Product serialization and traceability mandates Increasing threats to patient safety from counterfeited, adulterated, and diverted pharmaceutical
More informationA Global Review of Good. Brought to you by Cold Chain IQ
A Global Review of Good Distribution Practices Brought to you by Cold Chain IQ Contents v Introduction 3 v GDP Goes International 4 v Updates 5 v Worldwide Regulations 10 v More Regulations 12 v A One
More informationHealthcare Good Distribution Practice (GDP)
Healthcare Good Distribution Practice (GDP) 10 March 2018 Copyright silverbacklogistics.com. All rights reserved The place to go for free supply chain advice 1 The role of the MHRA Ensuring that medicines
More informationQ&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document
Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions
More informationSupersedes Division Name Revision No. 0 Export Division Page No. 1 of 9
Page No. 1 of 9 Control Status 1.0 Purpose To lay down a procedure for conducting GMP inspection and report writing for issue of Written Confirmation for for medicinal products for human. 2.0 Scope This
More informationGuide to Quality System for General Sale Wholesale Distributors
Guide to Quality System for General Sale Wholesale Distributors IA-G0038-5 20 DECEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationDr Christine Oechslein. from Beginner to Advanced Level and Beyond. A Step-by-Step Guide. GMP Fundamentals
Dr Christine Oechslein GMP Fundamentals A Step-by-Step Guide from Beginner to Advanced Level and Beyond Overview 1 The purpose of GMP 5 2 Basic pharmaceutical terms 13 3 Laws, licences and inspections
More informationISO INTERNATIONAL STANDARD. Cosmetics Good Manufacturing Practices (GMP) Guidelines on Good Manufacturing Practices
INTERNATIONAL STANDARD ISO 22716 First edition 2007-11-15 Corrected version 2008-05-15 Cosmetics Good Manufacturing Practices (GMP) Guidelines on Good Manufacturing Practices Cosmétiques Bonnes Pratiques
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationQA 2 / 2011 OCCURRENCE OF REVENUE FROM SALE OF GOODS
QA 2 / 2011 OCCURRENCE OF REVENUE FROM SALE OF GOODS MAY 2011 INTRODUCTION 1. Revenue is used not only by the company s management but also by various other external stakeholders such as investors and
More informationUSP General Chapter <1079> Pharmacopeia Forum. for Drug Products
USP General Chapter Pharmacopeia Forum Good Storage and Transportation Practices for Drug Products IATA Vancouver/March 8-12, 2010 Mary Foster, PharmD USP Expert Committee Member, 2005-2010 2010
More informationGIRP comments on. The vital link in healthcare 1. European Association of Pharmaceutical Full-line Wholesalers
GIRP comments on Guidelines on the principles of Good Distribution Practices for active substances for medicinal products for human use submitted for public consultation Introduction: GIRP, the European
More informationExcipient Certification Scheme
Excipient Certification Scheme CPhI Breakfast Briefings Feria de Madrid, 13 th October 2009 Dr Arnulf Heubner Member of the EFCG-Board and Chairman of the Pharmaceutical Business Committee (PBC) Excipient
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationMICROBIOLOGICAL CULTURE MEDIA
MICROBIOLOGICAL CULTURE MEDIA A COMPLETE GUIDE FOR PHARMACEUTICAL AND HEALTHCARE MANUFACTURERS Tim Sandle Microbiological Culture Media: A Complete Guide for Pharmaceutical and Healthcare Manufacturers
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationHow does the GDP guidelines impacted DGF on Local and Global level. 25 june 2013
How does the GDP guidelines impacted DGF on Local and Global level. 25 june 2013 Overview Introduction Who is DHL? What is GDP? DGF services Global approach DGF services Belgium 2 Introduction Elledin
More informationSafety Features Required by the Falsified Medicines Directive 2011/62/EU
TOPRA Annual Human Medicines Symposium 2017 Safety Features Required by the Falsified Medicines Directive 2011/62/EU Syed Qadri, Global Regulatory Affairs Strategy EU/ROW Jazz Pharmaceuticals Syed.Qadri@jazzpharma.com
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationGMP In-house Training
Your benefits: Customised to fit your company s requirements - cost-effective and flexible! GMP In-house Training for the Pharmaceutical, API and Medical Device Industry We offer practice-oriented GMP
More informationReducing Risk and Costs in the Global Supply Chain
Reducing Risk and Costs in the Global Supply Chain Global Quality & Compliance Services for the Life Sciences Industry sensitech.com @sensitech Protecting the Life Sciences Supply Chain Can Be Costly Maintaining
More informationInspection of API Manufacturers & Update on Registration Process
Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers
More informationYour Complete Quality Solution Provider for the Life Science Industry
Your Complete Quality Solution Provider for the Life Science Industry PQE at-a-glance Our broad services portfolio, extensive experience, effective project management, and exceptional cost effectiveness,
More informationPHARMACEUTICAL DEVELOPMENT
CONTENTS PHARMACEUTICAL DEVELOPMENT Table of Acronyms - Abbreviations Introduction Preface Forward VIII XIII XV XVI XVII Chapter 1 Regulatory 1.1 - Pre-formulation checklist 1.3 Documentation 1.4 - SOP
More informationUNICEF Quality Assurance in the procurement of medicines
UNICEF Quality Assurance in the procurement of medicines Peter S. Jakobsen October 2008 Quality Assurance Centre SUPPLY DIVISION 2 Today s presentation addresses 3 questions: How do UNICEF manage quality
More informationEuropean Union (EU) Regulatory Trends in GMP. Clive Brading Tianjin, China September 23, 2009
European Union (EU) Regulatory Trends in GMP Clive Brading Tianjin, China September 23, 2009 -2- Presentation Topics EU Background Inspections outside the EU EMEA Inspection Outcomes Dedicated Facilities
More informationImpact of WHO Guidelines on GMP for Blood Establishments
Impact of WHO Guidelines on GMP for Blood Establishments Christian Schärer, Ph.D. Swissmedic, Swiss Agency for Therapeutic Products, Head Inspectorate International Conference of Drug Regulatory Authorities
More informationIt s Simple. Protect the integrity of your products and your brand during cold chain transportation.
99 Washington Street Melrose, MA 02176 Phone 781-665-1400 Toll Free 1-800-517-8431 Visit us at www.testequipmentdepot.com It s Simple. Protect the integrity of your products and your brand during cold
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationQualification and validation: - an inspector s perspective. Ian Rees, Unit Manager Inspectorate Strategy
Qualification and validation: - an inspector s perspective Ian Rees, Unit Manager Inspectorate Strategy GMP - basics A system within an organisation (or linked organisations) to assure the quality of its
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More information